High-throughput protein engineering platform on the cellular secretory pathway, with offices between Palo Alto and Helsinki.
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Seed Avenue Biosciences raised a $5.7 million seed extension co-led by Balnord and Tesi to scale its therapeutic protein manufacturing platform. | $5.7M |
| Oct 2024 | Seed Avenue Biosciences raised $2.5M in seed funding led by Voima Ventures to advance its AI protein engineering platform. | $2.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.